

💲 sciendo

Treatment of Jumper's Knee with Extracorporeal Shockwave Therapy: A Systematic Review and Meta-Analysis

by

Magdalena Stania¹, Tomasz Król², Wojciech Marszałek¹, Justyna Michalska¹, Piotr Król¹

The aim of this systematic review and meta-analysis was to determine the therapeutic efficacy of extracorporeal shockwave therapy (ESWT) for athletes with patellar tendinopathy. We searched PubMed, EBSCOHost and Ovid for randomized controlled trials (RCTs) which evaluated the therapeutic efficacy of ESWT in athletes with jumper's knee. The methodological quality of RCTs was rated with the Physiotherapy Evidence Database scale. Data in the meta-analysis were expressed as standardized mean difference (SMDs) and 95% confidence intervals (CIs). Heterogeneity was assessed with I² statistics. Of 192 records identified, a total of seven articles met the inclusion criteria. The ESWT and control groups with any other conservative treatment did not differ significantly with respect to the Visual Analogue Scale (VAS) long-term scores obtained at ≥ 6 months of therapy completion (SMD: -0.33; 95% CI: -4.64 to 3.98; p = 0.87; I² = 98%). Furthermore, no significant differences were found between the ESWT and control groups regarding the pooled Victorian Institute of Sports Assessment for Patella (VISA-P) scores for long-term outcomes (SMD: 8.21; 95% CI: -39.3 to 55.73; p = 0.73; I² = 99%). The ESWT and control groups did not differ significantly on the VAS and VISA-P scores for long-term outcomes. In both cases, heterogeneity was considered to be high. Hence, no clear and generalized conclusions can be drawn regarding ESWT effectiveness in athletes with patellar tendinopathy.

Key words: patellar ligament, physical therapy modalities, musculoskeletal system, athletes.

Introduction

Patellar tendinopathy (commonly called jumper's knee) is a degenerative condition of the knee extensor mechanism which is caused by overloading and accumulation of microinjuries (Rudavsky and Cook, 2014). A literature review has found that horizontal landing poses the greatest risk for patellar tendinopathy (Van der Worp et al., 2014). Hence, athletes that jump frequently during competition and practice are at an increased risk of developing patellar tendinopathy with the overall prevalence from 8.5 to 14.2% (Lian et al., 2005; Zwerver et al., 2011). The type of sports training also affects the prevalence of jumper's knee (Lian et al., 2005). The highest prevalence was found among volleyball players, i.e., 14.4% and 44.6% in Lian et al.'s (2005) and Zwerver et al.'s (2011) studies, respectively, and basketball players (31.9%) (Lian et al., 2005). Non-jumping and repetitive low loading activities (e.g., swimming, running, cycling) do not put much stress on the patellar tendon and therefore, the risk of developing jumper's knee is rather low (Rhind et al., 2022; Rudavsky and Cook, 2014).

Patellar tendinopathy reduces the quality of life and interferes with engagement in vigorous physical and frequently, also professional sports activity. Fifty-five per cent of active athletes with

¹ - Institute of Sport Sciences, Academy of Physical Education, Katowice, Poland.

² - Department of Kinesitherapy and Special Methods, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland.

patellar tendinopathy report a negative impact on their sports performance, while 16% admit reduced work ability (de Vries et al., 2015). Clinical manifestations in athletes tend to be moderate, but long-lasting causing the sufferers to seek effective therapies (Kettunen et al., 2002) which would allow them to return to professional *sports* and physical *activity*.

Early symptoms of jumper's knee are usually managed conservatively. Pain reduction involves physical interventions, e.g., laser sonotherapy or transfer energetic therapy, capacitive and resistive therapy (commonly referred to as TECAR therapy) (Costantino et al., 2005). Other therapeutic options include the use of infrapatellar straps (Dar and Mei-Dan, 2019) and platelet rich plasma, high-volume image-guided injections of saline (Abate et al., 2018). Conservative treatment unsuccessful after 3 to 6 month therapy may indicate a need for surgery (Rodriguez-Merchan, 2013).

Although extracorporeal shockwave therapy (ESWT) has long been used as a conservative treatment for patellar tendinopathy, its curative effect on degenerative changes within tendons has not been fully elucidated. Neither have clear-cut recommendations for professional and amateur athletes been developed regarding the optimal ESWT variables.

Therefore, the aim of the current systematic review and meta-analysis was to determine the therapeutic efficacy of ESWT in athletes with patellar tendinopathy. The research question was defined by the PICO-model in accordance with the updated guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Page et al., 2021): Population: athletes with patellar tendinopathy; Intervention: extracorporeal shockwave therapy; Comparator: sham treatment or any other conservative treatment; Outcomes: pain intensity assessed with the Visual Analogue Scale (VAS) for a short- and a long-term followup; patient-reported functional outcomes assessed with the Victorian Institute of Sport Assessment-Patella (VISA-P) for a short- and a long-term follow-up. We believe that conclusions of this review and meta-analysis will help athletes, coaches and physical therapists adhere to standard ESWT therapies for a variety of sports.

Methods

Data Sources and Searches

A search was conducted using the

following databases: PubMed, EBSCOHost and Ovid according to the PRISMA statement (Page et al., 2021). The last search was carried out on the 5th of June, 2021. Keywords including 'patellar tendinopathy', 'tendinitis', 'tendinopathy', 'patellar tendon', 'enthesopathy', 'shockwave 'shock wave therapy', therapy', 'shock-wave therapy', 'extracorporeal shockwave', 'ESWT', 'extracorporeal shockwave therapy', extracorporeal shockwave', 'focused 'radial extracorporeal shockwave therapy', 'therapy' and 'treatment' were used in various configurations. Reference lists of all the retrieved articles were manually checked for additional studies. The full search strategies for all databases, including any filters and limits used, are presented in Appendix A (Table A.1.).

Study Selection

The papers were checked for relevant content and were included based on the following criteria: (1) full-text article published in English; (2) randomized controlled trials (RCTs); (3) trials in which athletes with patellar tendinopathy were treated with ESWT; (4) trials in which controls underwent sham treatment or any other conservative treatment (e.g., exercise, injections, physical therapy); (5) trials containing the comprehensive description of ESWT (the following application variables were reported: the number of shocks, frequency, energy flux density or pressure, the number of sessions, frequency of treatment).

We excluded trials using ESWT to treat knee cartilage disorders. Studies in animals were not included either. Conference abstracts, proceedings, case reports, commentary articles, secondary analyses, designs of RCTs, systematic reviews, meta-analyses and narrative reviews were also excluded (Stania et al., 2019). The results of the study selection procedure are summarized in the PRISMA 2020 flow diagram (Figure 1).

Data Extraction and Quality Assessment

Three authors (MS, TK, WM) independently searched for articles, screened studies, and extracted data in a blinded manner. Any disagreements between the authors were resolved through consensus, with other research team members (JM and PK) acting as arbiters. Data were extracted from each study on participant characteristics, intervention (type of shock wave therapy, description of procedures), outcomes (primary and secondary outcomes, methods and timing of assessment) and results.

The methodological quality of randomized clinical studies was rated with the Physiotherapy Evidence Database (PEDro) scale. The PEDro scale (ranging from 1 to 10 points) is a valid measure of the methodological quality of randomized clinical trials (de Morton, 2009).

Based on the PEDro score, the methodological quality of trials is rated as high (PEDro scores \geq 7), medium (4 to 6), or low (PEDro scores \leq 3) (Liao et al., 2018). The methodological quality of the included articles was assessed by three reviewers (MS, TK, WM). In the event of disagreement, consensus was sought by involving another researcher (JM).

Meta-analysis of effect estimates

Meta-analysis was undertaken where data were available from more than one study assessing the same outcome. The analysis included original papers which compared the outcomes of ESWT (as a monotherapy) with those of other conservative (non-surgical) therapies. Two outcomes were taken into consideration, i.e., pain reduction assessed with the Visual Analogue Scale and functional improvement verified using the Victorian Institute of Sports Assessment for Patella (VISA - P). Analyses were carried out for long-term scores obtained at \geq 6 months of therapy completion (a long-term follow-up). It was not possibile to undertake the meta-analysis for the short-term scores as there was only one study which met the inclusion criteria.

Data in the meta-analysis were expressed as standardized mean differences (SMDs) and 95% confidence intervals (CIs). Heterogeneity was assessed with l^2 statistics: 25% was considered low, 50% moderate, and 75% high. Statistical significance was set at p < 0.05. The random effects model was applied for the pooled effect estimates.

Results

Search Results

The search and databases yielded a total of 192 articles, of which only 7 met the inclusion criteria (Figure 1). The total pooled sample size of all of the included studies was 155 participants in the experimental group and 156 participants in the control group.

Quality Assessment

Table 1 summarizes the methodological quality of randomized clinical trials included in our review that were rated with the PEDro scale. The methodological quality of randomized clinical trials included in this review was rated as high (Lee et al., 2020; Vetrano et al., 2013; Zwerver et al., 2011) or medium (Cheng et al., 2019; Taunton et al., 2003; Wang et al., 2007).

Results of meta-analysis

The meta-analysis did not reveal significant differences between the ESWT and control groups regarding the Visual Analogue Scale long-term scores obtained at \geq 6 months of therapy completion (SMD: -0.33; 95% CI: -4.64 to 3.98; *p* = 0.87) (Figure 2). However, significant heterogeneity was observed with respect to long-term pain reduction (*I*² = 98%, *p* < 0.0001).

No significant differences were also found between the ESWT and control groups on the pooled VISA-P scores in the long-term follow-up (SMD: 8.21; 95% CI: -39.3 to 55.73; p = 0.73; $I^2 = 99\%$) (Figure 3).

Discussion

According to our meta-analysis, pooled estimates for VAS and VISA-P scores of the longterm follow-ups did not differ significantly between the ESWT and control groups, with confidence intervals crossing the line of no effect (Figures 2 and 3). For most of the cases, heterogeneity was considered to be high (*P*: 98-99%). Therefore caution should be taken when interpreting these results. Also, no clear and generalized conclusions can presently be drawn regarding ESWT effectiveness in athletes with patellar tendinopathy.

Studies with high quality PEDro scores revealed a reduction in subjective patellar tendinopathy complaints at one week of shockwave therapy in 65% of athletes (Zwerver et al., 2011). At the 6- and 12-month follow-up, the improvement was noted in 65.2% and 60.8% of athletes, respectively (Vetrano et al., 2013). However, although shockwave intervention proved to be an effective treatment of jumper's knee, it did not turn out superior to placebo therapy (Zwerver et al., 2011) or platelet-rich plasma injections (Vetrano et al., 2013). A combination of eccentric exercises and extracorporeal shockwave therapy also failed to increase treatment efficacy in athletes with jumper's knee (Lee et al., 2020; Thijs et al., 2017). Medium quality studies on jumper's knee showed greater efficacy of extracorporeal shockwave therapy compared to the placebo intervention (Taunton et al., 2003) and other forms of conservative treatment (Wang et al., 2007). At the 2- to 3-year follow-up, the overall clinical results were excellent in 43%, good in 47% and fair in 10% of athletes treated with shockwave therapy (Wang et al., 2007).

Differences in therapeutic efficacy of ESWT for patellar tendinopathy might be attributed to a couple of determinants described below. Table 2 shows the main characteristics of each intervention and key conclusions of the authors studying the efficacy question.

Athletes with patellar tendinopathy – characteristics Differences in therapeutic efficacy of ESWT could be attributed to large diversity across research materials including elite athletes during the competitive season (Lee et al., 2020; Zwerver et al., 2011), athletes in their off-season (Vetrano et al., 2013), individuals engaged in recreational sports (Wang et al., 2007) as well as patients of hospitals or sports medicine centers (Thijs et al., 2017). Each of these populations may have different etiological factors, e.g., the mechanical load on the patellar tendon in elite and non-elite athletes is much greater than that of hospital patients. Therapeutic success of ESWT is thus more difficult to reach in athletic populations as indicated by the studies of Zwerver et al. (2011) and Vetrano et al. (2013). It is also important that athletes do not engage in intensive physical activity during the therapy period. Zwerver et al. (2011) suggested that the total load on the tendon resulting from the combination of ESWT-induced

collagen disorganization and the mechanical overload from sports training might be too high and the time for recovery was insufficient. Consequently, some interference with potential regenerative effects of ESWT might be expected. Therefore, some researchers recommended that their athletes would not engage in physical activity during therapy and up to six weeks following therapy completion (Vetrano et al., 2013; Vulpiani et al., 2007; Wang et al., 2007).

Researchers mainly recruited athletes with a history of over 3-month chronic patellar tendinopathy (Lee et al., 2020; Taunton et al., 2003; Wang et al., 2007; Zwerver et al., 2011). Only Thijs et al. (2017) included those who had suffered for a period of eight weeks. Timely differentiation between acute and chronic tendinopathy is essential for diagnostic and therapeutic considerations (Gabel, 1999). Zwerver et al. (2011) did not show superiority of ESWT intervention over the placebo treatment for reduction of jumper's knee symptoms. According to the authors ESWT might fail in athletes suffering from reactive tendinopathy or early tendon dysrepair in the continuum of tendon pathology. ESWT proved beneficial in the degenerative stage of tendon disease (Zwerver et al., 2011).

Reference	1	2	3	4	5	6	7	8	9	10	11	Score*
Taunton et al., 2003	+	+	-	+	+	-	-	+	-	+	-	5
Wang et al., 2007	+	+	-	+	-	-	+	+	-	+	+	6
Zwerver et al., 2011	+	+	+	+	+	-	+	+	+	+	+	9
Vetrano et al., 2013	+	+	-	+	-	-	+	+	+	+	+	7
Thijs et al., 2017	+	+	+	+	+	-	+	+	+	+	+	9
Cheng et al., 2019	+	+	-	+	-	-	-	-	-	+	+	4
Lee et al., 2020	+	+	+	+	+	-	-	+	+	+	+	8

 Eligibility criteria specified; 2: Subjects randomly allocated to groups; 3: Allocation concealed; 4: Groups similar at baseline; 5: Blinding of all subjects; 6: Blinding of all therapists; 7: Blinding assessors; 8: >85% follow up; 9: Intention-to-treat analysis; 10: Between-group statistical comparison; 11: Point and variability measures. *Eligibility criteria item is not included in PEDro score calculations

Ref.	Sample size	Groups	Intervention	Outcome measure	Follow-up
Taunton et al., 2003	20	I: ESWT II: placebo ESWT	FSWT: 2000 shocks; 0.17 mJ/mm²; 3 to 5 sessions	VISA; vertical jump test	3 to 4 weeks after the third treatment, 3 to 4 weeks after the fifth treatment, at the 12 th week after the last treatment session
Wang et al., 2007	50	I: ESWT II: traditional conservative treatment	FSWT: 1500 shocks; 0.18 mJ/mm²; 1 session	VAS; VISA; ultrasonographic examination	1, 3, 6 and 12 months
Zwerver et al., 2011	62	I: ESWT II: sham ESWT	FSWT: 2000 shocks; 4 Hz; 0.1–0.58 mJ/mm ² ; 3 sessions, once a week	VISA-P; VAS	1, 12, and 22 weeks
Vetrano et al., 2013	46	I: autologus platelet-rich plasma II: ESWT	FSWT: 2400 shocks; 0.17–0.25 mJ/mm ² ; 3 sessions at 48- to 72-h intervals	VISA-P; VAS; modification of the Blazina scale	2, 6 and 12 months
Thijs et al., 2017	52	I: ESWT + eccentric training II: placebo ESWT + eccentric training	FSWT: 1000 shocks; 4 Hz; 0.2 mJ/mm ² ; 3 sessions, once a week	VAS; VISA-P; Likert score	6, 12 and 24 weeks
Cheng et al., 2019	51	I: ESWT II: control group (acupuncture, ultrasonic wave, microwave therapy)	RSWT: 2000 shocks; 9-12 Hz; 1.5 – 3 bars; (corresponds to 0.09-0.27 mJ/mm ²); 16 sessions, once a week	VAS; isokinetic muscle strength test	After therapy (16 weeks)
Lee et al., 2020	30	I: exercise group (eccentric exercise + sham ESWT) II: combined group (eccentric exercise + ESWT)	FSWT: 1500 shocks; 4 Hz; from 0.08 mJ/mm ² to the level that the subject could maximally tolerate; 6 sessions, once a week	VAS; VISA-P; ultrasonography; dynamometry	After therapy (12 weeks)

ESWT – Extracorporeal Shock Wave Therapy; FSWT – focused shockwave therapy; RSWT – radial shock wave therapy; VAS – Visual Analog Scale; VISA-P – Victorian Institute of Sport Assessment–Patella questionnaire

PubMed						
(((patella	tendinopathy[tia	b] or pai	tellar tendinitis[tia	ab] or jumper	's knee[tiab] or entesopathy[tw])	AND (shock wave[tiab]
or shock-	wave[tiab] or shoc	kwave[tiab] or shockwav	es[tiab] or ex	tracorporeal[tiab])) AND (therap	y[tiab] or
Eilter ann	[tiab])) lied. English					
FRSCON	neu: English					
TX (nate	llar tendinonathy (or natell	a tendinonathy or	r iumpers kne	e or patellar tendinitis or patella	tendinitis)
AND TX	(shockwave thera	pv or sh	ock wave therapy	v or shock-wa	ve therapy or extracorporeal sho	ockwave)
AND TX	(therapy or treatn	nent)	lock wave ulerupy	y of shock we	we unerupy of extracorporeur site	(chivave)
Filters ap	plied:	/				
- English	-					
- abstract	available					
Ovid ME	DLINE(R) ALL					
1	Patellar Ligament	t/ and Te	endinopathy/ 356	6		
2	(patellar tendinop	oathy or	patellar tendinitis	s or jumpers l	knee).mp. [mp=title, abstract, ori	ginal title, name of
substance	word, subject hea	ading wo	ord, floating sub-h	neading word	, keyword heading word, organ	ism supplementary
concept v	vord, protocol sup	plement	tary concept word	l, rare disease	supplementary concept word, u	inique identifier,
eunonum	s] 707					
synonym	, , , , , , , , , , , , , , , , , , ,	1	1 1	1 1		1 1 11
3	(shock wave or sh	nock-wa	ve or shockwave	or shockwave	es or extracorporeal).mp. [mp=tit	le, abstract, original title,
3 name of s	(shock wave or sh ubstance word, su	nock-wa ibject he	ve or shockwave o ading word, float	or shockwave ing sub-head	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor	le, abstract, original title, d, organism
3 name of s suppleme	(shock wave or shubstance word, su entary concept wo	nock-wa ibject he rd, proto 55428	ve or shockwave o ading word, float ocol supplementar	or shockwave ing sub-head ry concept we	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier	(shock wave or shubstance word, su entary concept wo , synonyms] 2 and 3 – 62	nock-wa ibject he rd, proto 55428	ve or shockwave o ading word, float ocol supplementar 3	or shockwave ing sub-head ry concept we	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4	(shock wave or shubstance word, su entary concept wo , synonyms] 2 and 3 62 limit 4 to english	nock-wa Ibject he rd, proto 55428 57	ve or shockwave o ading word, float ocol supplementar 3	or shockwave ing sub-head ry concept we	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo , synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float ocol supplementar	or shockwave ing sub-head ry concept wo	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo , synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float ocol supplementar	or shockwave ing sub-head ry concept wo	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo , synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave (ading word, float ocol supplementar 3	or shockwave ing sub-head ry concept we	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo , synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave (ading word, float ocol supplementar	or shockwave ing sub-head ry concept we	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo , synonyms] 2 and 3 62 limit 4 to english	iock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float ocol supplementar	or shockwave ing sub-head ry concept wo	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo , synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float pcol supplementar	or shockwave ing sub-head ry concept wo	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title, d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float pcol supplementar	or shockwave ing sub-head ry concept wo	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float ocol supplementar	or shockwave ing sub-head ry concept we	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float pcol supplementar p	or shockwave ing sub-head ry concept we	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary	le, abstract, original title d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wo synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float ocol supplementar <u>Ider</u>	or shockwave ing sub-head ry concept we ntification of st	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary udies via databases	le, abstract, original title d, organism concept word, unique
3 name of s suppleme identifier, 4 5	(shock wave or sh ubstance word, su entary concept word, synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float col supplementar <u>Ider</u> <u>Records identified f</u> <u>- PubMed (n = - EBSCOhost</u>	or shockwave ing sub-head ry concept we ntification of st rom: = 55) t (n = 80)	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary udies via databases	le, abstract, original title d, organism concept word, unique
3 name of s suppleme identifier 4 5	(shock wave or sh ubstance word, su entary concept wor , synonyms] 2 and 3 62 limit 4 to english	nock-wa ibject he rd, proto 55428 57	ve or shockwave o ading word, float ocol supplementar	or shockwave ing sub-head ry concept we ntification of st iom: = 55) ((n = 80) LINE	es or extracorporeal).mp. [mp=tit ing word, keyword heading wor ord, rare disease supplementary udies via databases Records removed before screening: Duplicate records	le, abstract, original title, d, organism concept word, unique







Williams et al. (2017) suggested that MRI should be performed in those athletes with refractory patella tendinopathy who failed conservative treatment. MRI scans help determine the location and involvement of the fat pad. If the scans reveal intratendon changes only, ESWT might be expected to yield good outcomes. Athletes with fat pad involvement should undergo arthroscopic debridement without ESWT.

Differences in the outcomes of ESWT might also be accounted for by differences in the initial severity of jumper's knee symptoms as assessed with the Victorian Institute of Sport Assessment–Patella questionnaire (VISA – P) (Zwerver et al., 2011).

Types of ESWT

Jumper's knee has much more frequently been treated with focused extracorporeal shockwave therapy (Lee et al., 2020; Thijs et al., 2017; Zwerver et al., 2011) than radial ESWT (Cheng et al., 2019). Focusing of shockwaves on a small-volume tissue target requires an accurate lesion location by ultrasounds. Radial ESWT allows treatment of both well-localized and more extensive lesions (Król et al., 2009).

Van der Worp et al. (2014) compared the efficacy of radial (3 therapy sessions, 2000 pulses, 8 Hz, 2.4 bars) and focused ESWT (3 therapy sessions, 2000 pulses, 4 Hz, 0.12 mJ/mm²) in athletes with patellar tendinopathy. Both treatment approaches reduced pain complaints and improved athletes' function. However, none of the methods proved superior.

While treating patellar tendinopathy, most researchers used three sessions of ESWT (Thijs et al., 2017; Vetrano et al., 2013; Zwerver et al., 2011), with a one-week interval in between (Cheng et al., 2019; Lee et al., 2020; Thijs et al., 2017; Zwerver et al., 2011). There were also shorter intervals of 2 days (Vetrano et al., 2013). Wang et al. (2007) only held one therapeutic session, while Cheng et al. (2019) sixteen sessions. The results of a meta-analysis revealed that duration of the intervention affected treatment results in athletes with knee tendinopathy and those with other soft tissue disorders as well (Liao et al., 2018). Long intervention periods (\geq 1 month) exhibited beneficial therapeutic effects of ESWT on reducing pain and improving functional outcomes, while shorter treatments were less effective irrespective of the type of the

extracorporeal shockwave (Liao et al., 2018).

With regard to radial ESWT, the number of shocks per session was 2000 (Cheng et al., 2019; van der Worp et al., 2014); the pulse frequency was 8 Hz (van der Worp et al., 2014) or 9–12 Hz (Cheng et al., 2019). The number of focused ESWT pulses was 1500 to 2500 and the pulse frequency was 4 Hz (Lee et al., 2020; Wang et al., 2007; Zwerver et al., 2011). For neuromuscular dysfunction, the effect of shockwave therapy tended to be dose-dependent and caused symptom improvement over time (Wang et al., 2007). The intensity of radial shockwaves applied for patellar tendinopathy was 1.5-3 bars (Cheng et al., 2019; van der Worp et al., 2014), whereas in focused shockwave therapy, the energy flux density was 0.08-0.58 mJ/mm² (Lee et al., 2020; Taunton et al., 2003; Wang et al., 2007; Zwerver et al., 2011).

Vetrano et al. (2013) recommended that chronic tendinopathies should be treated with focused ESWT at an energy flux density of 0.08 to 0.17 mJ/mm². A meta-analysis of randomized controlled trials also showed that athletes with knee tendinopathies and other soft tissue disorders treated with low-energy (below 0.2 mJ/mm²) focused shockwaves exhibited higher rates of treatment success and noticeable functional improvement compared to those who received high-energy treatments. The inverse results were observed for radial shockwave therapy (Liao et al., 2018).

Depending jumper's on knee manifestations, focused extracorporeal shockwaves were typically applied to the most painful spot within the patellar tendon (Thijs et al., 2017; Wang et al., 2007; Zwerver et al., 2010, 2011), a maximum of two specific points of tenderness (Taunton et al., 2003) or on the bonetissue junction of the patellar or tibial insertions of the patellar tendon (Peers et al., 2003; Vetrano et al., 2013). Radial shockwaves were directed onto the distal pole of the patella and patellar tendon. The area of maximal tenderness was treated circumferentially, starting at the most painful site (Furia et al., 2013).

Klonschinski et al. (2011) concluded that application of local anesthesia inhibited the effect of low-energy extracorporeal shockwave therapy on nociceptors and therefore, should not be used during extracorporeal shockwave therapies. Otherwise, low-energy extracorporeal shockwave 132

therapy is usually quite well tolerated (Vetrano et al., 2013; Wang et al., 2007; Zwerver et al., 2011). Only rarely have adverse effects been observed during or after ESWT interventions. Some athletes may complain of transient post-therapy skin reddening, but no bruising (Vetrano et al., 2013), moderate pain that occurs during the treatment, but resolves following treatment completion (Peers et al., 2003) or transient numbness and hypoesthesia (Wang et al., 2007).

ESWT can be used as monotherapy (Taunton et al., 2003; Wang et al., 2007; Zwerver et al., 2011) or can be combined with other treatment modalities, e.g., eccentric exercises (Lee et al., 2020; Thijs et al., 2017; van der Worp et al., 2014). However, a combination therapy had no additional effect compared to the shamshockwave/eccentric group (Thijs et al., 2017). Those authors also warned against using very intensive eccentric exercises in combination with ESWT (Thijs et al., 2017).

Evaluations of ESWT efficacy

The efficacy of ESWT for patellar tendinopathy was mainly evaluated using subjective measures (Thijs et al., 2017; Vulpiani et al., 2007; Wang et al., 2007; Zwerver et al., 2011) such as the Visual Analog Scale for pain (VAS Pain) (Cheng et al., 2019; Furia et al., 2013; Lee et al., 2020; Peers et al., 2003) and the Victorian Institute of Sport Assessment–Patella (VISA – P) questionnaire (Lee et al., 2020; Wang et al., 2007; Zwerver et al., 2010, 2011). The VISA score is a reliable index of the severity of patellar tendinopathy and shows excellent short-term testretest, and inter-tester reliability as well as good short-term stability (Visentini et al., 1998). It should be noted though that the Likert score (Thijs et al., 2017), the Blazine Scale and its modification (Vetrano et al., 2013; Vulpiani et al., 2007) and the Roles and Maudsley score (Furia et al., 2013; Peers et al., 2003) were also used.

Some other authors relied on objective measurements, including ultrasound

examination, to evaluate the vascularization in the area of the patellar tendon (Taunton et al., 2003; Wang et al., 2007), dimension and thickness of the patellar tendon, the presence of edema or swelling within the tendon (Wang et al., 2007). Cheng et al. (2019) explored the effects of extracorporeal shockwave therapy in athletes with patellar tendinopathy using isokinetic strength tests. Tendon mechanical properties were also assessed with dynamometry (Lee et al., 2020).

Literature analysis clearly indicates a need for randomized clinical trials with objective measurements of ESWT outcomes in athletes with patellar tendinopathy.

Limitations of the study

This study has some limitations. Firstly, our analysis included a limited number of studies investigating the therapeutic efficacy of ESWT in athletes with patellar tendinopathy. Secondly, excluding studies published in languages other than English could lead to language bias. Also, we might have missed randomized clinical trials published in different languages.

Conclusions

Extracorporeal shockwave therapy is a safe and non-invasive treatment for patellar tendinopathy. Contrary to surgical intervention, this form of therapy is not related to major complications or side effects; also, the patients do not need to take time off work. However, our meta-analysis did not reveal significant differences between ESWT and control groups with respect to the VAS and VISA-P scores for long-term outcomes. Hence, no definite conclusions on extracorporeal shockwave therapy efficacy for jumper's knee can be drawn. There is for high-methodological-quality а need randomized clinical trials that may facilitate clearcut recommendations regarding the methodology of ESWT interventions for patellar tendinopathy.

References

- Abate, M., Di Carlo, L., Verna, S., Di Gregorio, P., Schiavone, & C., Salini, V. (2018). Synergistic activity of platelet rich plasma and high volume image guided injection for patellar tendinopathy. *Knee Surgery*, *Sports Traumatology*, *Arthroscopy*, 26(12), 3645–3651.
- Cheng, L., Chang, S., Qian, L., Wang, Y., & Yang, M. (2019). Extracorporeal shock wave therapy for isokinetic muscle strength around the knee joint in athletes with patellar tendinopathy. *Journal of Sports Medicine and Physical Fitness*, 59(5), 822–827.

Costantino, C., Pogliacomi, F., & Vaienti, E. (2005). Cryoultrasound therapy and tendonitis in athletes: a

comparative evaluation versus laser CO2 and t.e.ca.r. therapy. Acta Biomedica, 76(1), 37-41.

- Dar, G., & Mei-Dan, E. (2019). Immediate effect of infrapatellar strap on pain and jump height in patellar tendinopathy among young athletes. *Prosthetics* and *Orthotics International*, 43(1), 21–27.
- de Morton, N.A. (2009). The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. *Australian Journal* of *Physiotherapy*, *55*(2), 129–33.
- de Vries, A.J., van der Worp, H., Diercks, R.L., van den Akker-Scheek, I., & Zwerver, J. (2015). Risk factors for patellar tendinopathy in volleyball and basketball players: A survey-based prospective cohort study. *The Scandinavian Journal of Medicine & Science in Sports*, 25(5), 678–84.
- Furia, J. P., Rompe, J.D., Cacchio, A., Del Buono, A., & Maffulli, N. (2013). A single application of low-energy radial extracorporeal shock wave therapy is effective for the management of chronic patellar tendinopathy. *Knee Surgery, Sports Traumatology, Arthroscopy*, 21(2), 346–50.
- Gabel, G.T. (1999). Acute and chronic tendinopathies at the elbow. *Current Opinion in Rheumatology*, 11(2), 138–43.
- Kettunen, J.A., Kvist, M., Alanen, E., & Kujala, U.M. (2002). Long-term prognosis for jumper's knee in male athletes. A prospective follow-up study. *The American Journal of Sports Medicine*, 30(5), 689–92.
- Klonschinski, T., Ament, S.J., Schlereth, T., Rompe, J.D., & Birklein, F. (2011). Application of local anesthesia inhibits effects of low-energy extracorporeal shockwave treatment (ESWT) on nociceptors. *Pain Medicine*, 12(10), 1532–7.
- Król, P., Franek, A., Zinka, W., Kubacki, J., Polak, A., & Franek, E. (2009). Focused and radial shock wave in orthopedics and physiotherapy. *Fizjoterapia Polska*, *9*(1), 1–20.
- Lee, W. C., Ng, G. Y., Zhang, Z. J., Malliaras, P., Masci, L., & Fu, S. N. (2020). Changes on tendon stiffness and clinical outcomes in athletes are associated with patellar tendinopathy after eccentric exercise. *Clinical Journal of Sport Medicine*, 30(1), 25–32.
- Lian, O. B., Engebretsen, L., & Bahr, R. (2005). Prevalence of jumper's knee among elite athletes from different sports: a cross-sectional study. *The American Journal of Sports Medicine*, 33(4), 561–7.
- Liao, C.D., Tsauo, J.Y., Chen, H.C., & Liou, T.H. (2018). Efficacy of extracorporeal shockwave therapy for lower-limb tendinopathy: a meta-analysis of randomized controlled trials. *American Journal of Physical Medicine & Rehabilitation*, 97(9), 605–619.
- Page, M. J., McKenzie, J. E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D. et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *British Medical Journal*, 372:n71.
- Peers, K.H., Lysens, R.J., Brys, P., & Bellemans, J. (2003). Cross-sectional outcome analysis of athletes with chronic patellar tendinopathy treated surgically and by extracorporeal shock wave therapy. *Clinical Journal of Sport Medicine*, 13(2), 79–83.
- Rhind, J. H., Dass, D., Barnett, A., & Carmont, M. (2022). A Systematic review of long-distance triathlon musculoskeletal injuries. *Journal of Human Kinetics*, *81*(1), 123–134.
- Rodriguez-Merchan, E.C. (2013). The treatment of patellar tendinopathy. *The journal of Orthopaedics and Traumatology*, 14(2), 77–81.
- Rudavsky, A., & Cook, J. (2014). Physiotherapy management of patellar tendinopathy (jumper's knee). *Journal of Physiotherapy*, 60(3), 122–9.
- Stania, M., Juras, G., Chmielewska, D., Polak, A., Kucio, C., & Król, P. (2019). Extracorporeal shock wave therapy for achilles tendinopathy. *BioMed Research International*, 26, 3086910.
- Taunton, K. M., Taunton, J., & Khan, K. (2003). Treatment of patellar tendinopathy with extracorporeal shock wave therapy. *British Columbia Medical Journal*, 45(10), 500–507.
- Thijs, K. M., Zwerver, J., Backx, F. J., Steeneken, V., Rayer, S., Groenenboom, P., & Moen, M. H. (2017). Effectiveness of shockwave treatment combined with eccentric training for patellar tendinopathy: a double-blinded randomized study. *Clinical Journal of Sport Medicine*, 27(2), 89–96.
- Van der Worp, H., de Poel, H. J., Diercks, R. L., van den Akker-Scheek, I., & Zwerver, J. (2014). Jumper's knee or lander's knee? A systematic review of the relation between jump biomechanics and patellar tendinopathy. *International Journal of Sports Medicine*, 35(8), 714–22.
- van der Worp, H., Zwerver, J., Hamstra, M., van den Akker-Scheek, I., & Diercks, R. L. (2014). No difference in effectiveness between focused and radial shockwave therapy for treating patellar tendinopathy: a randomized controlled trial. *Knee Surgery, Sports Traumatology, Arthroscopy,* 22(9), 2026–32.

- Vetrano, M., Castorina, A., Vulpiani, M. C., Baldini, R., Pavan, A., & Ferretti, A. (2013). Platelet-rich plasma versus focused shock waves in the treatment of jumper's knee in athletes. *The American Journal of Sports Medicine*, 41(4), 795–803.
- Visentini, P. J., Khan, K. M., Cook, J. L., Kiss, Z. S., Harcourt, P. R., & Wark, J. D. (1998). The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group. *Journal of Science and Medicine in Sport*, 1(1), 22–8.
- Vulpiani, M. C., Vetrano, M., Savoia, V., Di Pangrazio, E., Trischitta, D., & Ferretti, A. (2007). Jumper's knee treatment with extracorporeal shock wave therapy: a long-term follow-up observational study. *The Journal of Sports Medicine and Physical Fitness*, 47(3), 323–8.
- Wang, C. J., Ko, J. Y., Chan, Y. S., Weng, L. H., & Hsu, S. L. (2007). Extracorporeal shockwave for chronic patellar tendinopathy. *The American Journal of Sports Medicine*, 35(6), 972–8.
- Wang, C. J. (2003). An overview of shockwave therapy in musculoskeletal disorders. *Chang Gung Medical Journal*, 26(4), 220–32.
- Williams, H., Jones, S. A., Lyons, C., Wilson, C., & Ghandour, A. (2017). Refractory patella tendinopathy with failed conservative treatment-shockwave or arthroscopy? *Journal of Orthopaedic Surgery (Hong Kong)*, 25(1), 2309499016684700.
- Zwerver, J., Bredeweg, S. W., & van den Akker-Scheek, I. (2011). Prevalence of Jumper's knee among nonelite athletes from different sports: a cross-sectional survey. *The American Journal of Sports Medicine*, 39(9), 1984–8.
- Zwerver, J., Dekker, F., & Pepping, G. J. (2010). Patient guided piezo-electric extracorporeal shockwave therapy as treatment for chronic severe patellar tendinopathy: A pilot study. *The Journal of Back and Musculoskeletal Rehabilitation*, 23(3), 111–5.
- Zwerver, J., Hartgens, F., Verhagen, E., van der Worp, H., van den Akker-Scheek, I., & Diercks, R. L. (2011).
 No effect of extracorporeal shockwave therapy on patellar tendinopathy in jumping athletes during the competitive season: a randomized clinical trial. *The American Journal of Sports Medicine*, 39(6), 1191–9.

Corresponding author:

Magdalena Stania

Institute of Sport Sciences, Academy of Physical Education, Mikołowska 72a, 40-065 Katowice, Poland Tel: +48-32-2075129, fax: +48-32-2510197 E-mail address: m.stania@awf.katowice.pl